Carlsbad, California (March 2, 2023) - RCE Technologies, Inc. has just announced a major addition to the clinical team: the highly acclaimed Ronald P. Karlsberg, MD, FACC. As a Clinical Professor of Medicine at the prestigious Smidt Heart Institute at Cedars-Sinai and the David Geffen School of Medicine at UCLA, Dr. Karlsberg has established himself as a leader in clinical cardiology and is widely respected for his expertise in Preventive and Interventional Cardiology. He also serves as the President and one of the Founders of the Cardiovascular Research Foundation.
“Dr. Karlsberg is a clinical leader and physician executive. This is an exciting opportunity for RCE, and I’m thrilled he will join RCE at the cutting edge of transdermal biomarker research that could potentially transform clinical management of cardiovascular disease,” said RCE’s founder and CEO Atandra Burman.
Dr. Karlsberg has received hundreds of research grants, has published numerous peer reviewed papers and book chapters, and is a frequent invited speaker at local, national, and international meetings. With his early pioneering research in myocardial enzymes, myocardial infarction and particular interest in the integration of biomarkers in Preventive, Interventional Cardiology, and Advanced Imaging we are honored to have his expertise join the clinical team and accelerate clinical feasibility efforts for our technology.
In Dr. Karlsberg's own words, "I look forward to helping RCE advance clinical feasibility of its transdermal optical technology by conducting research in collaboration with top clinical institutions and finding the optimal integration of this technology in clinical practice. 'Point of care' determination of biomarkers has the potential to be transformational for the care of the cardiac patient and will save lives.”
About RCE:
RCE, an AI based med tech works towards the early detection of heart attacks. We have re-imagined the way cardiac proteins are monitored in the blood using a non-invasive transdermal technique. The instant reporting of one such protein, cardiac Troponin empowers emergency medicine physicians and cardiologists in the early assessment and appropriate risk stratification of patients presenting with chest pain. We currently are conducting clinical studies and undertaking premarket efforts.